New triple therapy for bladder cancer shows promise in early trial
NCT ID NCT05154994
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a combination of three drugs (tremelimumab, durvalumab, and belinostat) in people with advanced bladder cancer that has spread or cannot be removed surgically. The main goal is to find the safest dose and understand side effects. About 9 adults who have already tried other treatments or cannot take standard therapy are participating.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFILTRATING UROTHELIAL CARCINOMA, SARCOMATOID VARIANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New drug option for Hard-to-Treat cancers with FGFR3 mutations
- New bladder cancer drug aims to fight tumors without harming nerves
- New hope for advanced bladder cancer? bevacizumab combo tested
- New cocktail of drugs takes on Hard-to-Treat bladder cancer
- New imaging tracer could spot hidden cancers